biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by BearDownAZon Oct 22, 2017 2:44pm

144 Views

Post# 26842343

RE:RE:RE:RE:RE:Phase 0

Digitel,

You quoted this statement from the June News Release "The NHP studies will not directly impact the previously discussed phase 0 clinical trial in oncology." And you wondered whether planned/ongoing non-human primate may impact the Phase 0 study and asked "Does the risk involved in non-human primate testing now stand before phase 0 testing?"

I think JD summed it up perfectly. Go back and read his post. Again. And again. Until it sinks in.

You also asked "Given the size and complexity of a mouse brain compared to a non-human primate's brain isn't biodistribution a significant risk factor and that also explains why BTI is now testing it?"

Yes, a mouse brain is smaller than a non-human primate brain. I will give you that. However, a mouse brain is extremely similar to other mammalian brains, including primates. A non-human primate brain really isn't any more complex than a mouse brain.

These non-human primate studies should have been done a long time ago in my opinion and I am so happy that under Mark Day's leadership that they are prioritizing these experiments not only for the herceptin fusion by for their other pipeline candidates. But as JD pointed out, just because they are doing these studies while the clinical grade product is being finished, doesn't mean that this presents any additional risk or delay.

BearDownAZ

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale